Peter E.G.F. Ibrahim is a Computational Drug Discovery Scientist specialising in the integration of Quantum Mechanics, Artificial Intelligence, and Cheminformatics for early-stage drug design. A licensed pharmacist by background, he holds a Bachelor of Pharmacy from Ain Shams University, Cairo, and two Master's degrees in In-Silico Drug Design from the Universities of Caen Normandie and Paris Cité, France; the latter completed in partnership with the University of Cambridge. He completed his Wellcome Trust-funded PhD at the Drug Discovery Unit, University of Dundee, graduating in 2025. His doctoral research produced multiple published computational methodologies: 1) P-score, a dynamic binding pose scoring function integrating quantum mechanical FMO calculations with supervised molecular dynamics; 2) FMOPhore, a quantum-informed pharmacophore tool for hotspot identification in protein targets; 3) FrAncestor [4], a cheminformatics algorithm for fragment library design based on the Molecular Genealogy Tree framework; and 4) RVGrow [5], a reaction vector-based lead expansion tool for synthetically accessible fragment growing. His work has appeared in Nature Communications and the Journal of Computational Chemistry, with additional preprints. Peter has presented at over 20 international conferences, receiving first-place prizes at EuroQSAR, UKQSAR, the MGMS Young Modellers Forum (Oxford), CCPBioSIM (Edinburgh), and FBLD-2025 (Cambridge). Named Innovator of the Year 2023 by the University of Dundee, he secured over £25,000 in entrepreneurship awards; including the McGhee's and Venture Awards, funding the founding of his startup AQuSTx. He currently serves as Engineer in Residence at Nxera Pharma Co., Ltd., Cambridge, UK.